Latest / No Brain Behind / Beyond the Journal: Bringing MS Research Back to Communities
Transcript
- 1 00:00:00,000 --> 00:00:04,640 On behalf of the Society for Equity Neuroscience, welcome to No Brain Behind. 2 00:00:04,640 --> 00:00:13,520 The mission of the Society for Equity Neuroscience or Sequence is to enhance brain health 3 00:00:13,520 --> 00:00:19,600 equity through scientific research. This podcast is dedicated to conversations with equity-focused 4 00:00:19,600 --> 00:00:25,520 neuroscientists and thought leaders. Our guests are working to understand and address barriers 5 00:00:25,520 --> 00:00:31,040 to and facilitate us of optimal brain health and nervous system function for everyone, 6 00:00:31,040 --> 00:00:37,360 everywhere. No brain behind explores cutting-edge research methods, amplifies new discoveries, 7 00:00:37,360 --> 00:00:43,040 ambassadors, collaboration within the scientific community. I'm Dr. Githangeli Das. 8 00:00:43,040 --> 00:00:49,200 I am Dr. Annalkadeh Nathihada and I'm Dr. Chris Orlando. We are a clinician scientist in the 9 00:00:49,200 --> 00:00:55,760 field of health equity neuroscience who have the distant pleasure of being your host on No Brain 10 00:00:55,760 --> 00:01:03,680 Behind. Join us as explore the scientific challenges and innovations shaping the future of equity 11 00:01:03,680 --> 00:01:11,520 neuroscience. Many of our episodes talk to leaders in the field setting research agendas, 12 00:01:11,520 --> 00:01:15,760 researchers about their careers or recent discoveries, but today we want to focus on the 13 00:01:15,760 --> 00:01:20,240 step that comes after that, namely dissemination of our findings beyond the conferences and 14 00:01:20,240 --> 00:01:24,640 journals where they're published and into the communities represented by the findings. 15 00:01:24,640 --> 00:01:28,800 Today I have the great privilege of being joined by Holly Schmidt from the Accelerated 16 00:01:28,800 --> 00:01:35,600 Cure Project for MS and Dr. Christina Roman who is a researcher in cognition and aging in 17 00:01:35,600 --> 00:01:41,680 multiple sclerosis and other neurodegenerative conditions. The Accelerated Cure Project for MS or ACP 18 00:01:41,680 --> 00:01:46,240 has recently put together a guide for research dissemination to underrepresented groups with MS. 19 00:01:46,240 --> 00:01:52,080 Some of the resources and organizations identified are specific to MS, but the principles are 20 00:01:52,080 --> 00:01:56,800 certainly broadly applicable in health equity neuroscience, which is why we were excited to 21 00:01:56,800 --> 00:02:01,120 feature this work on the podcast. And we will include a link to where our listeners can find the 22 00:02:01,120 --> 00:02:05,440 toolkit and the document that we're describing today in case anyone is interested in learning more. 23 00:02:05,440 --> 00:02:10,000 One of my favorite things about working in the field of MS is the amazing organizations that we 24 00:02:10,000 --> 00:02:15,280 get to work with and the Accelerated Cure Project is one of my favorites. Holly, I would love if you 25 00:02:15,280 --> 00:02:20,320 introduce yourself and also tell us a little bit about the organization. Thank you so much, Chris, 26 00:02:20,320 --> 00:02:25,440 and thanks for having us here today. So my name is Holly Schmidt. I'm the vice president of scientific 27 00:02:25,440 --> 00:02:31,680 operations for Accelerated Cure Project or ACP as we call it. And I've been in this role for 28 00:02:31,680 --> 00:02:37,840 close to 25 years and I've seen so many amazing things happen in the field of MS as well as 29 00:02:37,840 --> 00:02:44,640 neuroscience more generally over that period of time. So ACP is a patient advocacy organization and 30 00:02:44,640 --> 00:02:51,680 nonprofit. We are research focused, so we're a little bit unusual, um, in that we conduct our own 31 00:02:51,680 --> 00:02:58,560 research and we also look for ways to support research that will produce outcomes and breakthroughs 32 00:02:58,560 --> 00:03:05,120 that will benefit the MS community. One of the things that we do is we create open access research 33 00:03:05,120 --> 00:03:11,280 resources. One of them is Bio repository of blood samples from people with MS and controls that 34 00:03:11,280 --> 00:03:17,280 can be requested by scientists all over the world. And we also have an enormous database that goes 35 00:03:17,280 --> 00:03:24,560 along with that that can also be requested. We also have a registry-like activity, but it's more 36 00:03:24,560 --> 00:03:31,040 patient-centered and patient-driven than typical registries and that's called iConquer MS. And that has 37 00:03:31,360 --> 00:03:38,320 I think now more than 11,000 people with MS who have signed up to join and conduct research with us. 38 00:03:38,320 --> 00:03:44,720 There are a couple of principles that guide our work that I wanted to point out. The first one is 39 00:03:44,720 --> 00:03:51,600 that we feel that people affected by MS should be included as partners in research, not just participants. 40 00:03:51,600 --> 00:03:58,400 They are the experts in living with the condition and their priorities are the ones that we feel are 41 00:03:58,400 --> 00:04:04,320 the most important to address. So whenever we do undertake research studies or 42 00:04:04,320 --> 00:04:10,800 building resources, we make sure that people with MS are part of the team. Our other principle that 43 00:04:10,800 --> 00:04:17,600 guides our work is that research should be inclusive and equitable. We came upon this understanding 44 00:04:17,600 --> 00:04:24,560 about 10 years ago when we were looking at who was enrolled in our repository and iConquer MS. And 45 00:04:24,560 --> 00:04:29,600 it was clear that even though we don't have the exact demographic breakdown of MS in the United States 46 00:04:29,600 --> 00:04:37,200 or elsewhere that the people that we had enrolled and recruited were very heavily white, very heavily 47 00:04:37,200 --> 00:04:43,280 non-Hispanic and not representative. And that's a problem because that means that the evidence base 48 00:04:43,280 --> 00:04:49,840 that we are generating and that our partners are generating is not going to be useful to everybody, 49 00:04:49,840 --> 00:04:56,000 won't be able to be applied to their own decisions. And so we said this is a problem, we need to do 50 00:04:56,000 --> 00:05:01,920 something about it, but we're also a very small organization and our resources are limited. 51 00:05:01,920 --> 00:05:06,720 So let's we thought let's partner with others. We know other people are also concerned about 52 00:05:06,720 --> 00:05:13,200 this specific situation and we don't have to go at alone. So we got funding from PCORI, which is the 53 00:05:13,200 --> 00:05:19,360 Patient Center.com's Research Institute to create the MS Minority Research Engagement Partnership 54 00:05:19,360 --> 00:05:28,480 Network or MRAPN for short. And that includes people with MS people who are clinicians or academic 55 00:05:28,480 --> 00:05:35,360 researchers. We have representatives of biopharmate industry organizations. We have people from other 56 00:05:35,360 --> 00:05:42,240 advocacy organizations and so on. And we've been working together for 10 years to understand the barriers 57 00:05:42,240 --> 00:05:49,280 and facilitators to diverse and inclusive recruitment into research studies and to create resources 58 00:05:49,440 --> 00:05:55,120 that those in our field can use. So we've done a very broad survey of people with MS about 59 00:05:55,120 --> 00:06:00,720 perceptions and experiences with research and that we did analyzed by racial and ethnic group. 60 00:06:00,720 --> 00:06:07,680 We created some toolkits for clinicians and researchers about under-representation research and 61 00:06:07,680 --> 00:06:15,280 their roles in helping to turn around that situation. And we also have created the document that 62 00:06:15,280 --> 00:06:22,720 will be discussing today. I have the privilege of working with Holly and Iconker MS in the Minority 63 00:06:22,720 --> 00:06:27,200 Research Engagement Partnership Network and several other projects. And I will say that my 64 00:06:27,200 --> 00:06:33,440 interactions with their patient advisory boards and councils have dramatically changed the course of 65 00:06:33,440 --> 00:06:38,800 a couple research projects that I'm actively pursuing. And it was with their input that those 66 00:06:38,800 --> 00:06:43,600 grant applications got funded and are being conducted. And so they are in addition to being a 67 00:06:43,600 --> 00:06:48,880 real pleasure to work with. They are a really powerful and impactful support for research that's going 68 00:06:48,880 --> 00:06:53,920 out and do a tremendous amount of good for other people living with MS. I also have the privilege of 69 00:06:53,920 --> 00:07:00,720 working with Dr. Christina Roman who is a neuropsychologist and with whom we have a number of collaborative 70 00:07:00,720 --> 00:07:04,320 projects. Dr. Roman if you would please tell us a little about your background in research. 71 00:07:04,320 --> 00:07:11,200 Thanks so much, Chris. And thank you so much for having me and it's so exciting to be on here with 72 00:07:11,200 --> 00:07:15,680 Holly as well. Because she and I have been working together closely for a number of years now. 73 00:07:15,680 --> 00:07:21,280 And I am currently an assistant professor of neurology and neuropsychology at the Keck School 74 00:07:21,280 --> 00:07:28,080 of Medicine of USC as well as a licensed clinical neuropsychologist. I have been conducting research 75 00:07:28,080 --> 00:07:34,800 with multiple sclerosis community for over 12 years now and currently use patient partnered 76 00:07:34,800 --> 00:07:41,040 approaches to investigate the impact of healthcare factors like access and quality of healthcare, 77 00:07:41,040 --> 00:07:48,560 medical comorbidities, on cognition and brain changes in underrepresented groups with MS, 78 00:07:48,560 --> 00:07:55,360 namely individuals who identify as Hispanic or Latina. And those individuals are aging with MS 79 00:07:55,360 --> 00:08:03,760 and the intention is to reduce health disparities and to find ways to intervene on cognitive decline 80 00:08:03,760 --> 00:08:10,640 that happens as we age. I've also been working closely with ACP including the MRI/PN 81 00:08:10,640 --> 00:08:16,320 for many years now and I'm so excited to be here to talk about research dissemination specific 82 00:08:16,320 --> 00:08:21,520 to the communities we work with because it's something that's actually a key tenant of ethical 83 00:08:21,520 --> 00:08:26,640 research and community oriented research but it often gets overlooked. Thank you so much 84 00:08:26,640 --> 00:08:32,560 both of you for joining us today. So I'd love to begin by asking, you know, what need was identified 85 00:08:32,560 --> 00:08:37,600 or in other words, what isn't happening that needs to happen and what was the plan that your group 86 00:08:37,600 --> 00:08:45,280 came up with to address it? Sure, I'll talk about this. So the MRI/PN had a brainstorming session in 87 00:08:45,280 --> 00:08:51,760 April of 2022. We had finished up a number of our projects and we wanted to take stock of where 88 00:08:51,760 --> 00:08:57,760 things stood at that time, where we wanted to go as a group and then how to get there and that would 89 00:08:57,760 --> 00:09:03,200 include ideas for collaborative projects that we could connect together. So a number of ideas were 90 00:09:03,200 --> 00:09:10,800 proposed and one of them was phrase like this, "Create a focus on systemic sharing of research results 91 00:09:10,800 --> 00:09:17,840 back to minority communities." And when we articulated the vision, like where would we want to be 92 00:09:17,840 --> 00:09:23,600 once we've worked on this for a bit, came out like this and I'll just read it. The results of MS 93 00:09:23,600 --> 00:09:29,760 clinical research are systematically communicated to minority communities including any findings that 94 00:09:29,760 --> 00:09:36,240 are relevant to specific populations. This consistent outreach shows respect for historically marginalized 95 00:09:36,240 --> 00:09:42,560 communities and builds trust in the research process leading to greater research engagement by 96 00:09:42,560 --> 00:09:48,240 members of these groups. So this was one of the ideas that motivated people to want to work on it 97 00:09:48,240 --> 00:09:54,480 together and we wound up having about 10 people from different stakeholder groups volunteering to 98 00:09:54,480 --> 00:10:02,320 be part of this team, including people affected by MS. One of those people said that they had participated 99 00:10:02,320 --> 00:10:09,920 in several studies but had never received research results from any of those studies. Other people 100 00:10:09,920 --> 00:10:16,720 spoke about building bridges and opening new dialogues through the sharing of research results. 101 00:10:16,720 --> 00:10:22,800 So we came together and decided that the way we were going to address this need was to develop 102 00:10:22,800 --> 00:10:28,800 a guidance document so that researchers would know exactly how and have the tools they needed to 103 00:10:28,800 --> 00:10:34,640 carry through on this vision. And so that was the origin and now I hand it over to Christina to 104 00:10:34,640 --> 00:10:40,560 describe what we actually did. Thanks Holly. With regard to the logistics of actually putting the 105 00:10:40,560 --> 00:10:46,080 document together, we worked together with stakeholders including diverse people living with MS. 106 00:10:46,080 --> 00:10:51,600 And really did an extensive literature search to identify previously published journal articles 107 00:10:51,600 --> 00:10:58,400 and guidelines that were tailored to diverse communities, namely with MS although that was a bit 108 00:10:58,400 --> 00:11:04,080 limited and so we also looked broadly across the literature with regard to dissemination and 109 00:11:04,080 --> 00:11:09,120 community partnered research. We then decided on key gaps that needed to be addressed and use the 110 00:11:09,120 --> 00:11:14,160 literature to try to fill these knowledge gaps and provide some important information around 111 00:11:14,160 --> 00:11:19,680 dissemination. The committee of this project worked together to draft each section and it went 112 00:11:19,680 --> 00:11:24,800 through several iterations to ensure that the spirit of the guidelines remained in line with our 113 00:11:24,800 --> 00:11:30,160 vision. And what was exciting is that we were able to present the initial draft of the document 114 00:11:30,160 --> 00:11:35,760 as a poster presentation at the 38th annual consortium of multiple sclerosis centers meeting. So 115 00:11:35,760 --> 00:11:41,920 that's one of the big MS conferences that happens every year. It took place in Nashville and we 116 00:11:41,920 --> 00:11:47,360 received a lot of great interest in feedback and began to disseminate our work and disseminate these 117 00:11:47,360 --> 00:11:53,040 guidelines so that other researchers and stakeholders could actually be able to use this document and 118 00:11:53,040 --> 00:11:59,280 use these guidelines and integrate it in their own work. The report identifies several barriers to 119 00:11:59,280 --> 00:12:04,240 communicating research findings. The first one is just a lack of acknowledgement and support for 120 00:12:04,240 --> 00:12:08,720 dissemination activities. Let's talk about why dissemination in these communities is so important. 121 00:12:08,720 --> 00:12:17,040 Yeah let's do that because we're asking scientists to extra work and we need to justify like why would 122 00:12:17,040 --> 00:12:22,080 you want to do that given that you're already so busy and already have so many challenges and constraints 123 00:12:22,080 --> 00:12:26,880 but there are really important reasons why it's good to take that extra time and effort to share 124 00:12:26,880 --> 00:12:32,800 the results with underrepresented communities. And we actually drew these reasons from surveys of 125 00:12:32,800 --> 00:12:37,440 researchers that were asked about you know why why should you do this or why would you want to do 126 00:12:37,440 --> 00:12:42,800 this. So this comes from researchers themselves that we found in the literature search. The first reason 127 00:12:42,800 --> 00:12:49,840 is an ethical one. Ethical obligation it is simply fair. It's just and fair to provide results to 128 00:12:49,840 --> 00:12:56,000 participants. Researchers stated that as an ethical obligation. Another reason for deliberately 129 00:12:56,000 --> 00:13:03,040 making an effort to share results with communities has to do with accessibility. Not everybody in the 130 00:13:03,040 --> 00:13:09,280 lay community in fact probably minority people in the lay community are familiar with finding medical 131 00:13:09,280 --> 00:13:14,720 journal articles, reading them, making sense of them. They can be very complex and technical. 132 00:13:14,720 --> 00:13:21,760 Even for those that have that ability there are other structural barriers in place such as pay 133 00:13:21,760 --> 00:13:27,120 walls you know not everybody can afford the money it costs to keep on top of the scientific literature 134 00:13:27,120 --> 00:13:33,360 even to access one article. So that's the reason why it's not enough just to say well the results are 135 00:13:33,360 --> 00:13:39,680 there go find them but to actually bring them into the public eye and also make them understandable. 136 00:13:39,680 --> 00:13:47,680 The reason is reciprocity. The people that participate in research study and the communities that 137 00:13:47,680 --> 00:13:54,480 support them are sharing gifts. They are sharing their time. They're sharing their data. They are 138 00:13:54,480 --> 00:14:00,000 sharing the results of their activities. Sometimes they're sharing the gift that they're putting 139 00:14:00,000 --> 00:14:06,160 themselves at potential risk for participating in a study. And these are gifts without which clinical 140 00:14:06,160 --> 00:14:12,800 research simply could not happen. And so we're asking scientists to think about what they can give 141 00:14:12,800 --> 00:14:18,240 and return when it comes to participants and their communities. An obvious answer to that is 142 00:14:18,240 --> 00:14:24,000 research results which participants have indicated are very important to them. So think about how 143 00:14:24,000 --> 00:14:29,680 you can not only receive gifts but give back. I think everybody wants to be a giver and not only a 144 00:14:29,680 --> 00:14:36,480 taker. And then finally the final benefit that we point out is that there are benefits to future 145 00:14:36,480 --> 00:14:42,080 research data from surveys of people who participate in clinical research shows that 146 00:14:42,080 --> 00:14:48,480 receiving the results back increases their trust and their willingness to participate in future 147 00:14:48,480 --> 00:14:55,040 studies. So sharing your findings for your current study can increase the amount of community 148 00:14:55,040 --> 00:15:01,680 support for your future studies and make it more likely that you can recruit, retain, etc. 149 00:15:01,680 --> 00:15:07,600 other people that are necessary for you to be successful in your work. Yes absolutely. As Holly 150 00:15:07,600 --> 00:15:13,040 pointed out the reasons for disseminating research findings to the greater MS community, especially 151 00:15:13,040 --> 00:15:18,880 more diverse or underrepresented communities that have participated in studies or even just live 152 00:15:18,880 --> 00:15:24,320 within the communities generally even if they have not been associated with research. They're just 153 00:15:24,320 --> 00:15:32,960 so salient clinical research. They are disseminating research is absolutely an ethical obligation of 154 00:15:32,960 --> 00:15:39,840 every researcher that conducts research with individuals. But in addition to talking about all the 155 00:15:39,840 --> 00:15:44,720 reasons to do it, we'd be remiss if we didn't talk about some of the barriers that also exist. 156 00:15:44,720 --> 00:15:51,120 So one of the barriers is often just a general lack of acknowledgement and support from funding 157 00:15:51,120 --> 00:15:57,360 agencies, institutions, and the academy at large. Oftentimes clinical researchers function under 158 00:15:57,360 --> 00:16:04,880 the age-old adage of publisher parish. And that is the constant message that's received is just 159 00:16:04,880 --> 00:16:11,440 you know get as many grants as you can, turn them out, publish, publish, publish, and as such many 160 00:16:11,440 --> 00:16:18,080 funding agencies and institutions focus on results in academic context only without leaving resources 161 00:16:18,080 --> 00:16:26,240 or room or time for dissemination. And what I would argue is that it's that's the most important part. 162 00:16:26,240 --> 00:16:33,360 It's the most important part to be able to disseminate to people, the participants, the community at 163 00:16:33,360 --> 00:16:39,440 large. And another struggle is that researchers have incentives and institutional support for 164 00:16:39,440 --> 00:16:44,480 publishing the results within the scientific and medical communities thinking about academic 165 00:16:44,480 --> 00:16:49,680 journals for example are going to scientific conferences. But not for really disseminating 166 00:16:49,680 --> 00:16:55,200 their findings to the patient community, especially underrepresented populations. So what do we do 167 00:16:55,200 --> 00:17:00,880 about that? Well, we need to make dissemination to the community a priority to change how it's viewed 168 00:17:00,880 --> 00:17:06,960 and supported. I encourage researchers to educate yourselves about your roles a researcher and your 169 00:17:06,960 --> 00:17:12,720 ethical obligation to the communities that you work with. It's especially crucial to understand 170 00:17:12,720 --> 00:17:17,680 history, the climate, the culture, and the values of your participants and the community that you 171 00:17:17,680 --> 00:17:22,720 work within. You know if you're working with the community, especially underrepresented community, 172 00:17:22,720 --> 00:17:29,200 you really need to take care and think about what you're doing and work even for a couple of years 173 00:17:29,200 --> 00:17:33,600 to build up to working with that community to understand and build those relationships 174 00:17:33,600 --> 00:17:39,520 and incorporate the topic of dissemination into conversations with your lab, with your colleague, 175 00:17:39,520 --> 00:17:45,920 the broader institution to ensure that dissemination is acknowledged and it becomes a common part of 176 00:17:45,920 --> 00:17:51,280 the research conversation, especially as it relates to underrepresented groups. We don't want this 177 00:17:51,280 --> 00:17:57,520 thing to be an afterthought. It's not just something that happens at the end of a study. We want this 178 00:17:57,520 --> 00:18:03,200 to be something that's integrated from even before you start putting together projects and grants. 179 00:18:04,480 --> 00:18:11,200 And so making it a part of the regular conversation is one step to make it a normal thing and that 180 00:18:11,200 --> 00:18:16,240 institutions understand the importance of it that your colleagues that everyone kind of is on 181 00:18:16,240 --> 00:18:20,560 the same page about the importance of dissemination. As you're listening to you, I'm just thinking 182 00:18:20,560 --> 00:18:25,600 back about a couple things. To Holly's point about the barriers to access, I'm just thinking about 183 00:18:25,600 --> 00:18:30,960 even as someone who's been training and working in this space for years now, how it's definitely the 184 00:18:30,960 --> 00:18:35,120 exception rather than the rule that I'm able to read an entire paper without having to reference 185 00:18:35,120 --> 00:18:39,280 two or three others just to understand what the authors are talking about. And so it's even just 186 00:18:39,280 --> 00:18:43,920 being able to access one article doesn't necessarily mean you're going to be able to digest and apply 187 00:18:43,920 --> 00:18:50,480 the findings. And the other thing I was thinking about is how each of our grants generally does include 188 00:18:50,480 --> 00:18:55,920 some requirement for a dissemination plan and it's almost exclusively academic conferences and 189 00:18:55,920 --> 00:19:01,040 things like that. And so we really do need to build into the infrastructure of our faculty reviews and 190 00:19:01,040 --> 00:19:05,680 our grant applications and things like that plans for more comprehensive dissemination to all the 191 00:19:05,680 --> 00:19:11,120 people that we owe that debt to. The second barrier identified in the document is failure to plan 192 00:19:11,120 --> 00:19:16,080 for dissemination. This is generally not emphasized in grant applications, publications, and so on. 193 00:19:16,080 --> 00:19:20,400 So it's easy to lose track of it if we're not intentional about including it from the earliest 194 00:19:20,400 --> 00:19:25,680 stages of study design. So how can researchers develop a plan for communicating results to 195 00:19:25,680 --> 00:19:30,320 underserved communities? That's a really great question, Chris. And I absolutely agree with you 196 00:19:30,320 --> 00:19:36,880 regard to the reading research articles and oftentimes that reading one just isn't enough because 197 00:19:36,880 --> 00:19:44,080 you do have to go to different articles and for us who navigate that all the time, you know, it can 198 00:19:44,080 --> 00:19:51,280 be difficult and there are pay walls. So to not have that available and not have easy access to 199 00:19:51,280 --> 00:19:57,200 results for the community is it just makes it that much harder to get information. So I absolutely 200 00:19:57,200 --> 00:20:03,280 agree with you. And with regard to, you know, how researchers can develop a plan for communicating 201 00:20:03,280 --> 00:20:09,040 results to underserved communities, it is such an important point in terms of dissemination. So many 202 00:20:09,040 --> 00:20:14,000 people here dissemination and think, ah, you know, that's something that I'll think about once the 203 00:20:14,000 --> 00:20:20,480 data's been collected and we actually have results to share. But the reality that is that in order to 204 00:20:20,480 --> 00:20:25,600 really be effective in disseminating your results to participants and the community at large, 205 00:20:25,600 --> 00:20:32,000 especially underrepresented communities where it's extra important, the plan has to start at the 206 00:20:32,000 --> 00:20:37,200 beginning when the study is being designed or the grant is being written. And that might shock some 207 00:20:37,200 --> 00:20:44,160 individuals. But it's actually key to think about a comprehensive dissemination plan and how it 208 00:20:44,160 --> 00:20:49,760 can be created. And there's actually really great resources online that map out how to develop a 209 00:20:49,760 --> 00:20:55,600 pre-project or pre-grant dissemination plan like you mentioned, Chris, that is not just to academic 210 00:20:55,600 --> 00:21:01,840 conferences or publications, but it's actually a roadmap of, okay, at the beginning of the study, 211 00:21:01,840 --> 00:21:05,440 this is what we're going to do. During the study, this is what we're going to do. And there is 212 00:21:05,440 --> 00:21:10,800 actually really great templates out there that are available for everyone to use. 213 00:21:10,800 --> 00:21:17,200 It's also important for grant funding applications since dissemination activities often need to be 214 00:21:17,200 --> 00:21:24,720 integrated into the budget from the beginning. And community input. So I cannot stress this enough. 215 00:21:24,720 --> 00:21:32,160 Community input and actually partnering with stakeholders, community for my studies, I have community 216 00:21:32,160 --> 00:21:39,200 advisory boards or a community stakeholder on all of my studies. And getting their input either through 217 00:21:39,200 --> 00:21:45,360 these different channels is crucial to ensure that the dissemination strategy is actually in 218 00:21:45,360 --> 00:21:51,680 mind with the community's needs and values. Because oftentimes researchers think one thing and they 219 00:21:51,680 --> 00:21:57,040 think that this is the right way to do something and then you go to the community and they're just like 220 00:21:57,040 --> 00:22:02,640 actually like that really does not work for us. And that's not the way that we like to hear about 221 00:22:02,640 --> 00:22:07,360 information or we don't have access to x, y, and z. And so that's not going to work for us. 222 00:22:07,360 --> 00:22:13,520 So it may be that community wants to stay updated about a study from beginning to end. For example, 223 00:22:13,520 --> 00:22:17,600 they want to know about recruitment. They want to know about preliminary results. They want to hear 224 00:22:17,600 --> 00:22:23,440 about any talks or presentations, even if they are going to be at conferences. So it's a study 225 00:22:23,440 --> 00:22:30,880 long process. And overall by planning early, you can more easily address costs, potential barriers, 226 00:22:30,880 --> 00:22:36,080 and dissemination should not just be an afterthought. It should actually be an integral part of a study 227 00:22:36,080 --> 00:22:41,760 again from the very beginning or even before the beginning of a project before it starts. 228 00:22:41,760 --> 00:22:48,160 Yeah, I just want to echo what you said about the importance of advisory boards. And for researchers 229 00:22:48,160 --> 00:22:55,440 who maybe haven't done that before, I would strongly encourage you to look into the patient advocacy 230 00:22:55,440 --> 00:23:00,640 and other patient organizations in your field of study because they may very well already have resources. 231 00:23:00,640 --> 00:23:06,160 And as we've already mentioned, the ACP for MS is a great example. I'll just share briefly my 232 00:23:06,160 --> 00:23:14,400 experience. I went to one of the patient councils that ACP and I conquer MS have with a study that I 233 00:23:14,400 --> 00:23:21,120 was developing an application for. And I sent them several scales that have been used in 234 00:23:21,120 --> 00:23:25,600 research, quantitative research in the past about different life experiences and such and ask them, 235 00:23:25,600 --> 00:23:30,720 like, do you feel like these do a good job of capturing your experiences? And then I met with them 236 00:23:30,720 --> 00:23:34,960 when we had a really in-depth like hour long discussion. And their response was generally like, 237 00:23:34,960 --> 00:23:41,760 yeah, these are fine, but really we just want an opportunity to tell our story. And that really just 238 00:23:41,760 --> 00:23:46,640 dramatically changed the course of my grant application. We changed it from a quantitative aim to a 239 00:23:46,640 --> 00:23:51,040 qualitative one. Yeah, I think it dramatically strengthened grant application. The grant 240 00:23:51,040 --> 00:23:55,920 application got funded and we're in the early stages of doing that qualitative work together. So, 241 00:23:55,920 --> 00:24:01,280 yeah, it is a really valuable and powerful approach to have people who are living with these 242 00:24:01,280 --> 00:24:07,600 conditions giving you input from even as early a study design and not just on the back end. 243 00:24:07,600 --> 00:24:13,680 While putting this document together, we had a lot of great conversations to that effect, similar 244 00:24:13,680 --> 00:24:20,560 to your experience, Chris, where we would bring up particular topics about different dissemination 245 00:24:20,560 --> 00:24:29,760 channels and individuals with lived experience who have MS had such great input about what works best 246 00:24:29,760 --> 00:24:38,320 for them, what works best for individuals affected by MS. And we very much considered that. We very 247 00:24:38,320 --> 00:24:45,760 much considered even individuals in particular communities who might face particular barriers to 248 00:24:45,760 --> 00:24:50,400 accessing some of the ways that we think about dissemination, you know, for thinking about 249 00:24:50,400 --> 00:24:57,520 requiring internet in order to access a website, for example, well, some people don't have internet. 250 00:24:57,520 --> 00:25:01,360 And so, what are some ways to get around that? What are some ways that we can make sure that 251 00:25:01,360 --> 00:25:09,920 everybody is able to access results and benefit from dissemination equitably? Those are 252 00:25:09,920 --> 00:25:16,240 really great points. And I've also had a really wonderful experience with the stakeholders and 253 00:25:16,240 --> 00:25:21,520 committees from ACP who have also shaped my project. So, I'm right there with you. 254 00:25:21,520 --> 00:25:26,080 So, what were some of the other barriers highlighted in the report and how can researchers address 255 00:25:26,080 --> 00:25:31,280 them as well? Yeah, so there were a few other barriers that were identified for disseminating research 256 00:25:31,280 --> 00:25:36,480 findings to underrepresented communities with MS and even communities without MS. And those include 257 00:25:36,480 --> 00:25:41,520 things like nondisclosure agreements, which may limit how much and when information can be shared. 258 00:25:41,520 --> 00:25:46,560 And in this case, we recommend that researchers work closely with their sponsor, their institution, 259 00:25:46,560 --> 00:25:52,480 to discuss balancing data protection and transparency. In these cases, it's important to emphasize 260 00:25:52,480 --> 00:25:57,600 the benefits gained by sharing progress and results with the community. And it also builds good 261 00:25:57,600 --> 00:26:03,040 well and trust in the study team and research community. Another barrier that sometimes occurs is 262 00:26:03,040 --> 00:26:09,520 having difficulty contacting patients after a study ends for a number of reasons or even concerns 263 00:26:09,520 --> 00:26:15,920 that sharing sensitive results may have unexpected consequences. So, first, you know, you want to ensure 264 00:26:15,920 --> 00:26:21,920 contact information is up to date that you have consent to provide study results even after the 265 00:26:21,920 --> 00:26:27,760 study and even creating a public website that can be accessed by participants and the community at large 266 00:26:27,760 --> 00:26:33,680 to keep up with the study at their own pace and even after the study ends because the strategy might 267 00:26:33,680 --> 00:26:38,960 not reach individuals with limited access to internet or a computer or a smartphone or those with 268 00:26:38,960 --> 00:26:45,440 limited digital skills. You may even consider consenting research participants to take part in an 269 00:26:45,440 --> 00:26:51,680 IRB-approved research repository that could allow contact by mail following the end of a study so you 270 00:26:51,680 --> 00:26:57,920 can send out newsletters or brief summaries or even just I've sent letters to folks and with regard 271 00:26:57,920 --> 00:27:03,840 to sharing potentially sensitive results, you know, consult with your institution's IRB or ethics 272 00:27:03,840 --> 00:27:10,080 committee and even ethicists. I know an ethicist that I've consulted with from the University of 273 00:27:10,080 --> 00:27:15,200 Washington who is absolutely amazing and has absolutely changed the way that I think about a lot of these 274 00:27:15,200 --> 00:27:20,880 things and so there's people out there and especially community advisory members, right? Again, 275 00:27:20,880 --> 00:27:26,400 going back to the community to obtain guidance on how to disseminate results in an informative yet 276 00:27:26,400 --> 00:27:32,240 sensitive way and also be available for questions or clarifications as they come up. You can't just 277 00:27:32,240 --> 00:27:37,840 work with a community and disappear. You have to be available and be there for them and even after 278 00:27:37,840 --> 00:27:43,040 the study ends and like many things in research and we've touched upon this a bit already, funding 279 00:27:43,040 --> 00:27:48,160 can be a notable barrier to being able to disseminate results throughout a study and this is even more 280 00:27:48,160 --> 00:27:54,560 of a concern given just the current funding landscape. If funding for dissemination isn't specifically 281 00:27:54,560 --> 00:28:00,560 included when the study budget is set, then it's likely going to be very difficult to find these 282 00:28:00,560 --> 00:28:06,720 funds once the study is started or concluded and other priorities are demanding the resources that 283 00:28:06,720 --> 00:28:12,800 you get from a particular grant. So we recommend that researchers budget for dissemination costs and 284 00:28:12,800 --> 00:28:18,560 grant applications and that's not possible then load and no cost options can be explored, you know, 285 00:28:18,560 --> 00:28:23,760 posting information on a lab or study website for example or again getting permission to do mailings. 286 00:28:23,760 --> 00:28:29,360 Also, there are sometimes opportunities to apply for funding that's specifically related to 287 00:28:29,360 --> 00:28:34,560 dissemination or capacity building and in these cases, you know, it's all about dissemination, 288 00:28:34,560 --> 00:28:39,360 it's all about building that capacity through dissemination and so those are other opportunities 289 00:28:39,360 --> 00:28:45,040 to get grant funding to engage in dissemination. I'll chime in here with an additional barrier that 290 00:28:45,040 --> 00:28:52,080 we point out in the document which is lack of experience with translating research results to 291 00:28:52,080 --> 00:28:58,000 the public. Lay language communication of scientific content doesn't always come naturally to people 292 00:28:58,000 --> 00:29:04,240 who are deep into conducting the research itself. Scientists may not be aware when they're using 293 00:29:04,240 --> 00:29:11,440 technical jargon and or abbreviations that aren't universally understood. So the document contains 294 00:29:11,440 --> 00:29:18,560 links to communication training resources and guidance on various topics, for example, translating 295 00:29:18,560 --> 00:29:24,800 information to other languages if the communities that you want to communicate with come from different 296 00:29:24,800 --> 00:29:30,080 backgrounds and countries. We also recommend seeking the help of members of the community that 297 00:29:30,080 --> 00:29:36,240 you want to communicate your results with. They can provide advice about what will resonate and also 298 00:29:36,240 --> 00:29:42,480 how to describe it. If a researcher doesn't have any personal connections with the community then 299 00:29:42,480 --> 00:29:49,040 we recommend reaching out to either your colleagues who might have some connections or as has been 300 00:29:49,040 --> 00:29:54,000 mentioned before with advocacy organizations that serve that community for their help. I also wanted 301 00:29:54,000 --> 00:30:01,680 to mention that the document contains three to four pages of tactical guidance. This is like a super 302 00:30:01,680 --> 00:30:06,560 down to earth guidance that researchers can apply when communicating their results to underserved 303 00:30:06,560 --> 00:30:11,760 communities. The topics that we cover include developing a communications plan that we talked 304 00:30:11,760 --> 00:30:18,640 about before, how to determine the target audiences that you want to reach out to, how to choose 305 00:30:18,640 --> 00:30:24,480 publication method as well as communications channels. There's also descriptions of different 306 00:30:24,480 --> 00:30:32,960 communications formats such as infographics, webinars, podcasts, plain language summaries and so on. 307 00:30:32,960 --> 00:30:38,960 And the document explains when and why you might use specific ones and then also importantly how to 308 00:30:38,960 --> 00:30:45,680 get started if you're not familiar with those forms of communications. And then finally we also wanted 309 00:30:45,680 --> 00:30:53,760 to make it as easy as possible for MS researchers specifically to connect to existing MS communication 310 00:30:53,760 --> 00:31:01,200 channels that could be enlisted as a conduit for their message. So we developed a directory of 10 311 00:31:01,200 --> 00:31:08,240 different MS advocacy organizations and individuals who produce various forms of content such as 312 00:31:08,240 --> 00:31:15,600 newsletters or podcasts or webinars. And we included the contact name, the email address and the phone 313 00:31:15,600 --> 00:31:22,800 number so that anybody using this resource can connect instantaneously with the person in charge. 314 00:31:22,800 --> 00:31:29,040 They don't even need to search online to find out the details. And this is actually the only part 315 00:31:29,040 --> 00:31:35,280 of the document that is specific to MS. The rest is relevant to researchers working in any aspect of 316 00:31:35,280 --> 00:31:41,120 neuroscience or health research in general I think. So I hope anybody who's listening will take the 317 00:31:41,120 --> 00:31:46,480 opportunity to read the guidance document and consider how you can apply it when sharing your own 318 00:31:46,480 --> 00:31:52,800 findings. So finally can you just share with us some success stories or some good examples of 319 00:31:52,800 --> 00:31:57,200 research being communicated back to communities represented in the findings and the impact that it had? 320 00:31:57,200 --> 00:32:04,800 I'll start. So I accelerated CURE project for MS does an amazing job at making study progress 321 00:32:04,800 --> 00:32:12,080 and results available to participants in the large RMS community. In 2022 we received a grant from 322 00:32:12,080 --> 00:32:19,440 PCORI to develop our capacity for disseminating research results. And we as a result of this 323 00:32:19,440 --> 00:32:25,360 development now post-lay summaries of our own research. And we're also happy to help share 324 00:32:25,360 --> 00:32:32,640 others findings in ways that are understandable and culturally sensitive. We also have partnership 325 00:32:32,640 --> 00:32:38,080 arrangements with other organizations who have their own podcasts and webinars and newsletters 326 00:32:38,080 --> 00:32:43,440 to expand the reach and accessibility of our communications. So you can see these 327 00:32:43,440 --> 00:32:51,600 lay summaries and other links at iconquerms.org. And if you go to research projects you will see 328 00:32:51,600 --> 00:32:56,640 what we posted so far. And you can also find out more about how we can help you disseminate your results. 329 00:32:57,440 --> 00:33:05,200 Yeah absolutely. So ACP I post a perfect example of how to disseminate research results in a very 330 00:33:05,200 --> 00:33:10,960 digestible way and it's very much available there for the MS community. There are also many other 331 00:33:10,960 --> 00:33:16,400 wonderful examples of active and impactful research dissemination to diverse groups within our 332 00:33:16,400 --> 00:33:22,640 guidance document. There's an entire section in fact of study dissemination examples including 333 00:33:22,640 --> 00:33:28,080 the Pasadon Clinical Study, the Reprieve Trial, Black Women's Health Study, those are just a couple of 334 00:33:28,080 --> 00:33:33,600 examples. But these all, you know, everything we have within this section in our document, 335 00:33:33,600 --> 00:33:40,160 they provide examples, guidelines, templates, infographics and videos that can help guide your 336 00:33:40,160 --> 00:33:46,080 own dissemination plan. And you can see what other groups have done that have been successful for them. 337 00:33:46,080 --> 00:33:52,000 Of course I always recommend you know making sure that you go back to who you're going to be working 338 00:33:52,000 --> 00:33:56,320 with, talk to stakeholders, talk to the community, you'll be working with to make sure that 339 00:33:56,320 --> 00:34:03,600 what you're choosing fits with the values and what works best for the community. But you know 340 00:34:03,600 --> 00:34:08,400 that just kind of scratches the surface and it gives you some ideas about what's possible. 341 00:34:08,400 --> 00:34:15,280 And some of the things out there I will say are incredibly amazing and just get you at least me 342 00:34:15,280 --> 00:34:19,600 get me just that much more excited about the research and being able to share the research. 343 00:34:20,560 --> 00:34:25,360 There's a lot of other research groups out there doing community, a true community partnered 344 00:34:25,360 --> 00:34:30,320 research that make ongoing communication and dissemination a priority. So there are people 345 00:34:30,320 --> 00:34:35,680 have been doing this for you know years and decades. So I also encourage the listeners to find 346 00:34:35,680 --> 00:34:39,920 these groups and learn from the researchers who have been doing this and who have been doing it 347 00:34:39,920 --> 00:34:45,920 correctly. And at the end of the day disseminating clinical research findings to underrepresented 348 00:34:45,920 --> 00:34:52,880 communities in MS research and beyond is just essential for promoting equity and trust within 349 00:34:52,880 --> 00:34:59,280 the healthcare system. Sharing results really fosters reciprocity, it benefits future research, 350 00:34:59,280 --> 00:35:04,960 if it feels ethical obligations and ensures accessibility for everyone. And so despite these 351 00:35:04,960 --> 00:35:11,920 potential barriers that we noted, there are strategies that exist to overcome the challenges 352 00:35:11,920 --> 00:35:16,800 and it's really not an excuse, you know, these barriers you can overcome them in different ways. 353 00:35:16,800 --> 00:35:22,480 And so by developing tailored dissemination plans and understanding your target audience, 354 00:35:22,480 --> 00:35:28,960 employing appropriate communication formats, researchers, we can actually effectively share 355 00:35:28,960 --> 00:35:34,320 our findings with the communities that we work with. And collaboration with community partners 356 00:35:34,320 --> 00:35:40,000 and stakeholders and advocacy groups is just imperative. You know, there's just no way around it. 357 00:35:40,000 --> 00:35:45,920 And this is because at the end of the day, you know, the long established adage of no research about 358 00:35:45,920 --> 00:35:52,560 us without us, very much applies. You need to build trust and true partnerships by giving back 359 00:35:52,560 --> 00:35:58,720 without anything expecting anything in return. And that's a major first step to growing the relationships 360 00:35:58,720 --> 00:36:04,480 needed in order to be able to build partnerships, to build dissemination plans. And once you're there 361 00:36:04,480 --> 00:36:09,840 using various communication channels is crucial for enhancing outreach efforts and ensuring 362 00:36:09,840 --> 00:36:16,560 dissemination materials are culturally sensitive and relevant. So overall, just being transparent 363 00:36:16,560 --> 00:36:22,480 and having inclusive research dissemination practices contribute to informed decision-making, 364 00:36:22,480 --> 00:36:28,000 empowering individuals affected by MS and other syndromes and disorders and factors. 365 00:36:28,000 --> 00:36:32,880 Christine, I 100% agree with everything you just said. And I will just add that people usually go 366 00:36:32,880 --> 00:36:38,400 into health research because they want to improve people's lives. And sharing your results with 367 00:36:38,400 --> 00:36:44,480 the community that they're intended to benefit can boost the impact of your work. I would say also 368 00:36:44,480 --> 00:36:50,880 if connecting and communicating with unfamiliar audiences seems a bit daunting, then just tap into 369 00:36:50,880 --> 00:36:57,360 your natural curiosity as a scientist and ask yourself, "Well, what will happen if I try contacting 370 00:36:57,360 --> 00:37:03,600 this advocacy organization?" Or, "What will happen if I ask a community member to co-develop an 371 00:37:03,600 --> 00:37:09,840 infographic with me?" You could be pleasantly surprised at where this could lead. And final thing I 372 00:37:09,840 --> 00:37:15,600 want to do is I know on a lot of podcasts, I listen to the guests in the house put in plugs for things 373 00:37:15,600 --> 00:37:21,680 they do. So I wanted to put in a plug for the MREPM, the Minority Research Engagement Partnership 374 00:37:21,680 --> 00:37:29,360 Network. It is an open network. Anybody can join it who is interested in improving MS Minority 375 00:37:29,360 --> 00:37:35,760 Research Inclusion and Diversity and Equity in the studies that we conduct. So you can contact 376 00:37:35,760 --> 00:37:42,480 me or you can go to AcceleratedCure.org and find our information about inclusive research there. 377 00:37:42,480 --> 00:37:48,240 And I'll also put in a plug for the Ride Council, which is what Chris mentioned as the advisory 378 00:37:48,240 --> 00:37:54,240 group that he met with. The Ride Council stands for Research Inclusion Diversity and Equity. 379 00:37:54,240 --> 00:37:58,880 It's a group of about 30 people with MS who come from different underrepresented backgrounds, 380 00:37:58,880 --> 00:38:05,920 including racial and ethnic minorities, rural residents, LGBTQ individuals, people with disabilities 381 00:38:05,920 --> 00:38:14,160 and so on. And they are available. They guide us at ACP in our research efforts. And they're also 382 00:38:14,160 --> 00:38:20,640 available to guide researchers like Chris and perhaps yourself if you would benefit from their 383 00:38:20,640 --> 00:38:26,320 expertise and their wisdom. Again, you can reach out to AcceleratedCure through the contact 384 00:38:26,320 --> 00:38:30,640 information on our website and we'll be happy to talk with you and connect you with that wonderful 385 00:38:30,640 --> 00:38:36,080 group. Well, as always, it has been a pleasure speaking with both of you. Thank you so much for your 386 00:38:36,080 --> 00:38:41,840 vision, for persons that are at MS Research. Your true partnership with these communities for your 387 00:38:41,840 --> 00:38:47,200 leadership in research dissemination and other key elements of partnering with communities affected 388 00:38:47,200 --> 00:38:51,120 by the conditions that we study. And thank you for joining us on No Brain Behind Today. 389 00:38:55,680 --> 00:39:00,240 Thank you for listening to No Brain Behind. No Brain Behind is the official podcast of the 390 00:39:00,240 --> 00:39:05,200 Society for Equity and Neuroscience. Opinions shared in this episode are those of the individuals 391 00:39:05,200 --> 00:39:10,240 being interviewed. To hear more from sequence, subscribe to the podcast, follow us on social media 392 00:39:10,240 --> 00:39:14,560 and give us feedback. And what we would like to hear in future episodes. No Brain Behind is brought 393 00:39:14,560 --> 00:39:20,640 to you by the Society for Equity and Neuroscience led by Dr. Bruce Obiagli and Liana Mesa Cure. 394 00:39:20,640 --> 00:39:25,360 This podcast is produced by Doctors Vanessa Cooper, Rachel Foreman and Parnit Graywall. 395 00:39:25,360 --> 00:39:30,320 And our production team includes Sonia Glitur, Tino Delamer said, Joshua Homs, 396 00:39:30,320 --> 00:39:43,760 UChain Huang and Jake Sausaman. Dr. Angel Kadina Tejada, Gitanjali Doss and Chris Orlando are hosts.